In Vitro Activities of DC-159a, a Novel Fluoroquinolone, against Mycobacterium Species

被引：47

作者：

Disratthakit, Areeya ^{[1
]}

Doi, Norio ^{[1
]}

机构：

[1] Japan Anti TB Assoc, Res Inst TB, Tokyo 2048533, Japan

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2010年 / 54卷 / 06期

关键词：

MURINE TUBERCULOSIS; MOXIFLOXACIN; GATIFLOXACIN;

D O I：

10.1128/AAC.01545-09

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The in vitro activities of DC-159a against seven species of Mycobacterium were compared with moxifloxacin, gatifloxacin, levofloxacin, and rifampin. DC-159a was the most active compound against quinolone-resistant multidrug-resistant M. tuberculosis (MIC(90), 0.5 mu g/ml) as well as drug-susceptible isolates (MIC(90), 0.06 mu g/ml). The anti-tubercle bacilli activity of DC-159a was 4- to 32-fold more potent than those of currently available quinolones. DC-159a also demonstrated the highest activities against clinically important nontuberculous mycobacteria.

引用

页码：2684 / 2686

页数：3

共 16 条

[1]

[Anonymous], 2003, Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes

[2]

Approved Standard. NCCLS document M24-A. NCCLS, 940 West Valley Road

[3] Comparison of in vitro activities of gatifloxacin and ciprofloxacin against four taxa of rapidly growing mycobacteria [J].

Brown-Elliott, BA ;

Wallace, RJ ;

Crist, CJ ;

Mann, L ;

Wilson, RW .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (10) :3283-3285

[4] In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci [J].

Clark, Catherine ;

Smith, Kathy ;

Ednie, Lois ;

Bogdanovich, Tatiana ;

Dewasse, Bonifacio ;

McGhee, Pamela ;

Appelbaum, Peter C. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (01) :77-84

[5] Gatiffoxacin in combination with rifampicin in a murine tuberculosis model [J].

Cynamon, Michael ;

Sklaney, Mary R. ;

Shoen, Carolyn .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2007, 60 (02) :429-432

[6] Minimising moxifloxacin resistance with tuberculosis [J].

Drlica, Karl ;

Zhao, Xilin ;

Kreiswirth, Barry .

LANCET INFECTIOUS DISEASES, 2008, 8 (05) :273-275

[7] Activity of moxifloxacin against mycobacteria [J].

Gillespie, SH ;

Billington, O .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 (03) :393-395

[8] Correlation between quinolone susceptibility patterns and sequences in the A and B subunits of DNA gyrase in mycobacteria [J].

Guillemin, I ;

Jarlier, V ;

Cambau, E .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (08) :2084-2088

[9] In vitro and in vivo antibacterial activities of DC-159a, a new fluoroquinolone [J].

Hoshino, Kazuki ;

Inoue, Kazue ;

Murakami, Yoichi ;

Kurosaka, Yuichi ;

Namba, Kenji ;

Kashimoto, Yoshinori ;

Uoyama, Saori ;

Okumura, Ryo ;

Higuchi, Saito ;

Otani, Tsuyoshi .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (01) :65-76

[10] Fluoroquinolones as chemotherapeuties against mycobacterial infections [J].

Jacobs, MR .

CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (26) :3213-3220

← 1 2 →